rabbit anti-thymocyte globulin

also known as Rabbit ATG · antithymocyte globulin (rabbit) · r-ATG · ATG-Fresenius · ATG · Thymoglobulin · Lapine T-Lymphocyte Immune Globulin · antithymocyte globulin · +18 more

Protein / enzyme biologic

Developed for: aplastic anemia · leukemia · myelodysplastic syndrome · end stage renal failure · sickle cell disease · acquired aplastic anemia · acute lymphoblastic leukemia · acute myeloid leukemia
+28 more
· bone marrow failure syndrome · disease related to hematopoietic stem cell transplant · graft versus host disease · immunodeficiency disease · liver disorder · lymphoma · paroxysmal nocturnal hemoglobinuria · plasma cell myeloma · transplant rejection · acquired thrombocytopenia · acute graft versus host disease · anemia · beta thalassemia · chronic myeloid leukemia · disease of orbital part of eye adnexa · hematologic disorder · histiocytosis · idiopathic aplastic anemia · IgA glomerulonephritis · inborn errors of metabolism · juvenile myelomonocytic leukemia · neuroblastoma · osteopetrosis · primary acquired red cell aplasia · relapsing-remitting multiple sclerosis · severe combined immunodeficiency · thalassemia · type 1 diabetes mellitus
Investigated by: Genzyme, a Sanofi Company · City of Hope Medical Center · Columbia University · M.D. Anderson Cancer Center · University of Cincinnati · University of Nebraska
+55 more
· Alberta Health services · Astellas Pharma Inc · California Institute for Regenerative Medicine (CIRM) · Canadian Institutes of Health Research (CIHR) · Children's Discovery Institute · Chinese PLA General Hospital · Clinical Trials in Organ Transplantation · European Society for Blood and Marrow Transplantation · Fondazione IRCCS Policlinico San Matteo di Pavia · Fred Hutchinson Cancer Center · Fresenius AG · Fujian Medical University · Hospital Clinic of Barcelona · Institut Klinické a Experimentální Medicíny · Institute for Clinical and Experimental Medicine · Institute of Hematology & Blood Diseases Hospital, China · Italian Association for Pediatric Hematology Oncology · King Faisal Specialist Hospital & Research Center · Masonic Cancer Center, University of Minnesota · McMaster University · Medical University of Silesia · Millennium Pharmaceuticals, Inc. · Ministry of Health, Czech Republic · National Cancer Institute (NCI) · National Heart, Lung, and Blood Institute (NHLBI) · National Institute of Allergy and Infectious Diseases (NIAID) · National Institute of Blood Disease Center, Pakistan · Neovii Biotech · New York Medical College · Otsuka America Pharmaceutical · Peking Union Medical College Hospital · Peking University People's Hospital · Pfizer · Prof. Dr. Petra Reinke · Prof. Dr. med. Wolfgang Bethge · Rising Tide Foundation · Sanofi · Scripps Health · St. Jude Children's Research Hospital · St. Louis Children's Hospital Foundation · The Canadian Blood and Marrow Transplant Group · The Leukemia and Lymphoma Society · Tianjin First Central Hospital · UNC Lineberger Comprehensive Cancer Center · University Hospital of Saint-Etienne · University Hospital, Basel, Switzerland · University Hospital, Tours · University Medical Center Hamburg-Eppendorf · University of Alberta · University of Calgary · University of Chicago · University of Rochester · Washington University School of Medicine · Weill Medical College of Cornell University · medac GmbH

Trials 44

today NCT07677306 · Ph 2 NCT06158828 · Ph 1/2 NCT06412497 · Ph 2 NCT05385432 · Ph 3 NCT06009965 · Ph 4 NCT05482542 · not/applicable NCT05293509 · Ph 2 NCT03980769 · Ph 2 NCT04776850 · Ph 0 NCT04395222 · Ph 2 NCT05199103 · not/applicable NCT05214066 · Ph 2 NCT03249831 · Ph 1 NCT03470961 · Ph 4 NCT03099122 · Ph 4 NCT04114188 · Ph 2 NCT02203396 · Ph 2 NCT01994824 · Ph 2 NCT02028416 · not/applicable NCT01856257 · Ph 2 NCT03631563 · Ph 2/3 NCT01729494 · Ph 4 NCT01582048 · Ph 2 NCT01049854 · Ph 2 NCT02523768 · Ph 4 NCT01217723 · Ph 3 NCT01129323 · not/applicable NCT00861536 · Ph 4 NCT00782821 · Ph 4 NCT00471848 · Ph 2 NCT01530555 · Ph 2 NCT00934557 · Ph 3 NCT00564538 · Ph 4 NCT00801931 · Ph 1/2 NCT00678275 · Ph 3 NCT00943800 · not/applicable NCT00436722 · Ph 2 NCT00317798 · Ph 1 NCT00260689 · Ph 2 NCT00448357 · Ph 1/2 NCT00556933 · Ph 4 NCT01019876 · Ph 2/3 NCT00186823 · Ph 3 NCT00190502 · not/applicable

2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030203120322033203420352036

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT04776850	Dec 2020 → Dec 2022	beta-thalassemia major, sickle cell disease, sickle cell-beta plus-thalassemia, sickle cell-beta zero-thalassemia	M.D. Anderson Cancer Center	Withdrawn	No outcome recorded Stop: Enrollment
Phase 12 trials
Phase 1	NCT03249831	Jan 2019 → Jan 2027 expected	sickle cell disease, thalassemia	City of Hope Medical Center	Active not recruiting	No outcome recorded
Phase 1	NCT00317798	Apr 2006 → Apr 2011	plasma cell myeloma, poisoning	University of Rochester	Completed	No outcome recorded
Phase 1/23 trials
Phase 1/2	NCT06158828	Nov 2024 → Sep 2028 expected	acute myeloid leukemia by FAB classification, childhood acute myeloid leukemia	Washington University School of Medicine	Recruiting	No outcome recorded
Phase 1/2	NCT00801931	Sep 2007 → May 2009	anemia, immunodeficiency disease, leukemia, lymphoma +1	Columbia University	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT00448357	Oct 2005 → Nov 2015	leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell neoplasm	UNC Lineberger Comprehensive Cancer Center	Completed	No outcome recorded
Phase 216 trials · 2 met primary · 2 missed
Phase 2	NCT07677306	Jul 2026 → Dec 2027 expected	myelodysplastic syndrome	Peking University People's Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT06412497	Jun 2024 → May 2035 expected	acquired thrombocytopenia, idiopathic aplastic anemia, paroxysmal nocturnal hemoglobinuria, primary acquired red cell aplasia	Masonic Cancer Center, University of Minnesota	Recruiting	No outcome recorded
Phase 2	NCT05293509	Mar 2022 → Sep 2023	disease related to hematopoietic stem cell transplant	M.D. Anderson Cancer Center	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2	NCT03980769	May 2021 → Jul 2028 expected	hematologic disorder	Fred Hutchinson Cancer Center	Recruiting	No outcome recorded
Phase 2	NCT04395222	Oct 2020 → Sep 2022 overdue	hematopoietic and lymphoid cell neoplasm	Weill Medical College of Cornell University	Active not recruiting	No outcome recorded
Phase 2	NCT05214066	Feb 2019 → Aug 2022	acute graft versus host disease, chronic graft versus host disease	Chinese PLA General Hospital	Unknown	No outcome recorded
Phase 2	NCT04114188	Dec 2016 → Dec 2020	transplant rejection	Prof. Dr. Petra Reinke	Completed	Met primary
Phase 2	NCT02203396	Aug 2014 → Sep 2016	aplastic anemia	Institute of Hematology & Blood Diseases Hospital, China	Completed	No outcome recorded
Phase 2	NCT01994824	Jan 2014 → Jun 2017	graft versus host disease	University of Calgary	Terminated	Met primary
Phase 2	NCT01856257	Jul 2013 → Apr 2016	—	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	Missed primary
Phase 2	NCT01582048	Apr 2012 → Aug 2016	disease related to hematopoietic stem cell transplant	Prof. Dr. med. Wolfgang Bethge	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01049854	Sep 2011 → Nov 2017	beta thalassemia, bone marrow failure syndrome, histiocytosis, immunodeficiency disease +4	New York Medical College	Completed	No outcome recorded
Phase 2	NCT00471848	Aug 2008 → Oct 2011	acquired aplastic anemia	European Society for Blood and Marrow Transplantation	Completed	No outcome recorded
Phase 2	NCT01530555	Apr 2008 → Jul 2013	acquired aplastic anemia	King Faisal Specialist Hospital & Research Center	Completed	No outcome recorded
Phase 2	NCT00436722	Jun 2006 → Jul 2009	liver disorder	Hospital Clinic of Barcelona	Terminated	Missed primary
Phase 2	NCT00260689	Nov 2005 → May 2016	neutropenia, pancytopenia, thrombocytopenia	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT03631563	Mar 2013 → Dec 2018	graft versus host disease	Fujian Medical University	Unknown	No outcome recorded
Phase 2/3	NCT01019876	Sep 2002 → Sep 2021	Fanconi anemia, bone marrow failure syndrome, osteopetrosis, severe combined immunodeficiency	Columbia University	Completed	No outcome recorded
Phase 35 trials · 2 met primary · 1 missed
Phase 3	NCT05385432	Nov 2023 → Dec 2030 expected	transplant rejection	University Hospital, Tours	Recruiting	No outcome recorded
Phase 3	NCT01217723	Apr 2010 → Jan 2014	hematopoietic and lymphoid system neoplasm	McMaster University	Unknown	Met primary
Phase 3	NCT00934557	Mar 2008 → ?	—	Fondazione IRCCS Policlinico San Matteo di Pavia	Unknown	Missed primary
Phase 3	NCT00678275	Oct 2006 → Feb 2014	acute lymphoblastic leukemia, acute myeloid leukemia	University Medical Center Hamburg-Eppendorf	Completed	Met primary
Phase 3	NCT00186823	Mar 2002 → Sep 2005	acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, juvenile myelomonocytic leukemia +2	St. Jude Children's Research Hospital	Completed	No outcome recorded
Phase 49 trials
Phase 4	NCT06009965	Jan 2023 → Jan 2025	aplastic anemia	Peking Union Medical College Hospital	Unknown	No outcome recorded
Phase 4	NCT03470961	Mar 2018 → Mar 2021	diabetes mellitus, end stage renal failure	Tianjin First Central Hospital	Unknown	No outcome recorded
Phase 4	NCT03099122	Aug 2017 → Nov 2019	end stage renal failure	Sanofi	Completed	No outcome recorded
Phase 4	NCT01729494	Sep 2012 → Dec 2018	—	University of Cincinnati	Completed	No outcome recorded
Phase 4	NCT02523768	Jan 2011 → Jan 2020	IgA glomerulonephritis	University Hospital of Saint-Etienne	Terminated	No outcome recorded
Phase 4	NCT00861536	Jan 2009 → Feb 2015	—	University Hospital, Basel, Switzerland	Completed	No outcome recorded
Phase 4	NCT00782821	Sep 2008 → Feb 2013	—	University of Cincinnati	Completed	No outcome recorded
Phase 4	NCT00564538	Dec 2007 → Dec 2009	liver disorder	University of Nebraska	Unknown	No outcome recorded
Phase 4	NCT00556933	Apr 2004 → Apr 2011	end stage renal failure	University of Nebraska	Completed	Mixed
Phase not applicable6 trials
—	NCT05482542	Jan 2023 → Jul 2027	relapsing-remitting multiple sclerosis	Scripps Health	Withdrawn	No outcome recorded Stop: Business
—	NCT05199103	Jan 2020 → Dec 2023	disease of orbital part of eye adnexa	Medical University of Silesia	Unknown	No outcome recorded
—	NCT02028416	Sep 2013 → Dec 2017	aplastic anemia	National Institute of Blood Disease Center, Pakistan	Unknown	No outcome recorded
—	NCT01129323	Nov 2009 → Sep 2011	aplastic anemia	City of Hope Medical Center	Withdrawn	No outcome recorded Stop: Enrollment
—	NCT00943800	Oct 2006 → Sep 2018	leukemia, myelodysplastic syndrome, plasma cell myeloma	University of Chicago	Completed	No outcome recorded
—	NCT00190502	Nov 2000 → Dec 2007	type 1 diabetes mellitus	Institute for Clinical and Experimental Medicine	Unknown	No outcome recorded
Comparator or background therapy67 trials
Phase 1	NCT07257419 Background	Aug 2026 → Dec 2031 expected	childhood acute lymphoblastic leukemia, disease related to hematopoietic stem cell transplant	St. Jude Children's Research Hospital	Recruiting	No outcome recorded
Phase 1	NCT05525507 Background	Dec 2022 → Dec 2026 expected	chronic transplant rejection, end stage renal failure	University of California, Los Angeles	Recruiting	No outcome recorded
Phase 1	NCT04521946 Background	Jan 2021 → Dec 2022	anaplastic ependymoma, atypical teratoid rhabdoid tumor, central nervous system germ cell tumor, choroid plexus carcinoma +3	M.D. Anderson Cancer Center	Withdrawn	No outcome recorded Stop: Enrollment
Phase 1	NCT03531736 Background	May 2018 → May 2026 overdue	myeloid hemopathy	Memorial Sloan Kettering Cancer Center	Active not recruiting	No outcome recorded
Phase 1	NCT02916979 Background	Sep 2016 → Jun 2019	Waldenstrom macroglobulinemia, lymphoid leukemia, myelodysplastic syndrome, myelofibrosis +2	Dartmouth-Hitchcock Medical Center	Completed	No outcome recorded
Phase 1	NCT02165007 Background	Jan 2015 → Jan 2024	sickle cell-beta-thalassemia disease syndrome, thalassemia	Catherine Bollard	Completed	No outcome recorded
Phase 1	NCT02188719 Background	Dec 2014 → Jun 2019	—	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 1	NCT02472392 Comparator	Apr 2013 → Dec 2016	Ewing sarcoma	University of Louisville	Completed	No outcome recorded
Phase 1	NCT01455506 Background	May 2009 → Dec 2013	acute myeloid leukemia, myelodysplastic syndrome	Hackensack Meridian Health	Completed	No outcome recorded
Phase 1	NCT00849888 Background	Apr 2008 → Feb 2011	DiGeorge syndrome	Sumitomo Pharma Switzerland GmbH	Terminated	No outcome recorded
Phase 1	NCT00325741 Background	Jun 2004 → Oct 2015	systemic lupus erythematosus	Stanford University	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT03597594 Comparator	Sep 2021 → Jul 2027 expected	severe combined immunodeficiency	St. Jude Children's Research Hospital	Active not recruiting	No outcome recorded
Phase 1/2	NCT04083183 Background	Jun 2020 → Jan 2028 expected	benign neoplasm	Fred Hutchinson Cancer Center	Recruiting	No outcome recorded
Phase 1/2	NCT04066114 Background	Dec 2019 → Sep 2023	disease related to solid organ transplantation	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/2	NCT04224558 Background	Nov 2019 → Sep 2027 expected	Crohn disease	Cedars-Sinai Medical Center	Recruiting	No outcome recorded
Phase 1/2	NCT02080195 Background	Sep 2016 → Mar 2017	graft versus host disease, lupus erythematosus	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT02166177 Background	Jun 2014 → Jan 2018	liver failure	Guy's and St Thomas' NHS Foundation Trust	Completed	No outcome recorded
Phase 1/2	NCT01050764 Background	Jun 2009 → Aug 2012	B-cell chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome	Everett Meyer	Terminated	No outcome recorded
Phase 1/2	NCT00579527 Background	Dec 2005 → Dec 2011	DiGeorge syndrome	Sumitomo Pharma Switzerland GmbH	Completed	No outcome recorded
Phase 2	NCT07508787 Comparator	Jun 2026 → Mar 2028 expected	transplant rejection	Nefro Avillion Clinical Development, LLC	Recruiting	No outcome recorded
Phase 2	NCT07570745 Background	May 2026 → May 2028 expected	acute graft versus host disease	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Recruiting	No outcome recorded
Phase 2	NCT05736419 Background	Feb 2023 → Feb 2027 expected	beta thalassemia, sickle cell disease	Memorial Sloan Kettering Cancer Center	Recruiting	No outcome recorded
Phase 2	NCT04688021 Background	Dec 2020 → Dec 2024	graft versus host disease, leukemia	Yi Luo	Unknown	No outcome recorded
Phase 2	NCT04202835 Background	Oct 2020 → May 2024 overdue	acute leukemia, chronic graft versus host disease, myelodysplastic syndrome	McMaster University	Active not recruiting	No outcome recorded
Phase 2	NCT04530487 Background	Aug 2020 → Aug 2024	Ewing sarcoma/peripheral primitive neuroectodermal tumor, desmoplastic small round cell tumor, malignant peripheral nerve sheath tumor, neuroblastoma +2	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 2	NCT03663335 Background	Nov 2018 → Oct 2021	—	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT03357159 Background	Sep 2018 → Dec 2024	graft versus host disease	Sheba Medical Center	Unknown	No outcome recorded
Phase 2	NCT03615144 Comparator	Jul 2018 → Nov 2020	hematologic disorder	Memorial Sloan Kettering Cancer Center	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT03600909 Background	May 2018 → Apr 2021	Fanconi anemia, acute myeloid leukemia, myelodysplastic syndrome	Memorial Sloan Kettering Cancer Center	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT03263559 Background	Oct 2017 → Jan 2025	sickle cell disease	Medical College of Wisconsin	Completed	No outcome recorded
Phase 2	NCT02828592 Background	Sep 2016 → Aug 2027 expected	aplastic anemia	Northside Hospital, Inc.	Recruiting	No outcome recorded
Phase 2	NCT02790515 Background	Jul 2016 → Jul 2025 overdue	acute lymphoblastic leukemia, chronic myeloid leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome +1	St. Jude Children's Research Hospital	Active not recruiting	No outcome recorded
Phase 2	NCT02404025 Background	May 2015 → Jul 2016	aplastic anemia	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT02143830 Background	Apr 2014 → Dec 2026 expected	Fanconi anemia, acute myeloid leukemia, bone marrow failure syndrome, myelodysplastic syndrome	Children's Hospital Medical Center, Cincinnati	Recruiting	No outcome recorded
Phase 2	NCT01790594 Background	Feb 2013 → Aug 2016	—	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	Missed primary Stop: Enrollment
Phase 2	NCT01745913 Background	Oct 2012 → Apr 2015	Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome	Weill Medical College of Cornell University	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01810588 Background	Oct 2012 → Aug 2023 overdue	hematopoietic and lymphoid cell neoplasm	Weill Medical College of Cornell University	Active not recruiting	No outcome recorded
Phase 2	NCT01621477 Background	Aug 2012 → Dec 2015	acute lymphoblastic leukemia, chronic myeloid leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome +1	St. Jude Children's Research Hospital	Terminated	No outcome recorded
Phase 2	NCT01565616 Background	Mar 2012 → Jun 2016	sickle cell disease	Emory University	Completed	No outcome recorded
Phase 2	NCT01461837 Background	Jan 2012 → Dec 2025 overdue	sickle cell disease	New York Medical College	Active not recruiting	No outcome recorded
Phase 2	NCT01517984 Background	Nov 2010 → May 2015	disease related to solid organ transplantation	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 2	NCT00899847 Background	May 2009 → Apr 2014	plasma cell myeloma	Stanford University	Completed	No outcome recorded
Phase 2	NCT00566696 Background	Dec 2007 → Jan 2016	Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia +3	St. Jude Children's Research Hospital	Completed	No outcome recorded
Phase 2	NCT00593554 Background	Aug 2007 → Aug 2016	acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome	Sherif S. Farag	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00230035 Comparator	Sep 2005 → ?	systemic lupus erythematosus	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2	NCT00186628 Background	Jun 2005 → Nov 2010	mantle cell lymphoma, mast cell leukemia	Stanford University	Completed	No outcome recorded
Phase 2	NCT00038857 Background	Sep 2001 → Jun 2009	leukemia, lymphoma	M.D. Anderson Cancer Center	Completed	No outcome recorded
Phase 2/3	NCT07412470 Background	Mar 2026 → Aug 2029 expected	transplant rejection	Sanofi	Recruiting	No outcome recorded
Phase 3	NCT05457556 Background	Mar 2023 → Jun 2026 overdue	acute lymphoblastic leukemia, mixed phenotype acute leukemia, myelodysplastic syndrome	Children's Oncology Group	Active not recruiting	No outcome recorded
Phase 3	NCT04547049 Comparator	Sep 2020 → Apr 2026 overdue	leukemia, myelodysplastic syndrome	First Affiliated Hospital of Zhejiang University	Active not recruiting	No outcome recorded
Phase 3	NCT00733733 Comparator	Jan 2008 → Jan 2010	—	Radboud University Medical Center	Unknown	No outcome recorded
Phase 3	NCT00316810 Comparator	Apr 2006 → Feb 2011	—	Dr. Claudia Bösmüller	Completed	No outcome recorded
Phase 3	NCT00105183 Comparator	Jan 2005 → Jan 2010	bronchiectasis, cystic fibrosis, idiopathic pulmonary fibrosis, vascular disorder	Neovii Biotech	Completed	No outcome recorded
Phase 4	NCT05634915 Comparator	Dec 2022 → Dec 2024	acute leukemia, disease related to hematopoietic stem cell transplant	The First Affiliated Hospital of Soochow University	Unknown	No outcome recorded
Phase 4	NCT04849533 Background	Apr 2021 → Jul 2023	transplant rejection	University of Cincinnati	Unknown	No outcome recorded
Phase 4	NCT03789006 Comparator	Mar 2018 → Mar 2022	transplant rejection	University of Khartoum	Unknown	No outcome recorded
Phase 4	NCT02838992 Background	Feb 2017 → Dec 2018	aplastic anemia	Jinan Military General Hospital	Unknown	No outcome recorded
Phase 4	NCT02784561 Background	Jul 2016 → Jul 2019	leukemia	Chinese PLA General Hospital	Unknown	No outcome recorded
Phase 4	NCT02274662 Background	Aug 2014 → Aug 2023	T-cell immunodeficiency, thymus gland disorder	Sumitomo Pharma Switzerland GmbH	Completed	No outcome recorded
Phase 4	NCT01950819 Background	Dec 2013 → Feb 2017	end stage renal failure	Novartis Pharmaceuticals	Completed	Met primary
Phase 4	NCT02218437 Background	Oct 2013 → Oct 2015	disease related to hematopoietic stem cell transplant	Chinese Academy of Medical Sciences	Unknown	No outcome recorded
Phase 4	NCT02377193 Comparator	Sep 2013 → Jan 2017	transplant rejection	University Hospital, Toulouse	Completed	No outcome recorded
Phase 4	NCT03377283 Comparator	Aug 2012 → Mar 2015	—	Medical University Innsbruck	Completed	No outcome recorded
Phase 4	NCT00596947 Background	Oct 2005 → Mar 2009	—	University of Pennsylvania	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00113269 Comparator	May 2005 → Mar 2009	—	Astellas Pharma Inc	Completed	No outcome recorded
—	NCT02936505 Background	Oct 2016 → Oct 2025 overdue	—	Vastra Gotaland Region	Active not recruiting	Met primary
—	NCT00859131 Comparator	Mar 2009 → Jul 2012	end stage renal failure	Medical University of South Carolina	Completed	No outcome recorded

Press releases naming this drug 2 releases

Date	Issuer	Release
2023-09-27	Scandinavian Biopharma AB	Scandinavian Biopharma and Neovii extend and expand their distribution agreement for the transplantation product Grafalon scandinavianbiopharma.se ↗
2022-09-07	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.	Neovii and Fosun Pharma Enter into an Exclusive Agreement for Development and Commercialization for Grafalon® in China fosunpharma.com ↗

Evidence & citations 30 cited values

Every value below carries the sentence it was read from. 122 sources stand behind the page.

Field	Value	Cited text
Known as	rabbit antithymocyte globulin	“A Non-randomized, Phase II Study of Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A (ATG/CsA) in Subjects With Moderate or More Severe Aplastic...” NCT02404025 ↗ 50 “In mesenchymal stem cells (MSC) group, UC-MSCs were injected intravenously at a dose of 1 × 106/kg per week starting on the 14th day after administration of rabbit...” PMID 33639900 ↗ Feb 2021 “Rabbit anti-thymocyte globulin (rATG), a polyclonal rabbit-derived antibody that depletes lymphocytes, including T cells, was introduced to prevent GVHD and transplant rejection.” NCT05634915 ↗ “Describe the pharmacokinetics of rabbit anti-thymocyte globulin (rATG) in patients receiving allogeneic transplantation and determine the frequency of rATG antibody development” NCT00186823 ↗ “Different outcomes between cyclophosphamide plus horse or rabbit antithymocyte globulin for HLA-identical sibling bone marrow transplant in severe aplastic anemia.” PMID 22796534 ↗ Jul 2012 “Patients will also receive rabbit antithymocyte globulin (Thymoglobulin) at a dose of 2 mg/kg IV daily for 3 days on transplant days -4, -3, and -2.” NCT01455506 ↗ “A Pilot, Phase-I Trial of Rabbit Anti-Thymocyte Globulin (rATG, Thymoglobulin™) in Combination With Rapamycin in Relapsed Multiple Myeloma (MM)” NCT00317798 ↗ “Patients will receive Thiotepa on Days -5, -4, Cyclophosphamide on Days -3, -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1.” NCT01049854 ↗ “Our previous case report has shown promising results for rabbit antithymocyte globulin (rATG) in the treatment of Graves' orbitopathy.” PMID 35615718 ↗ May 2022 “All subjects received induction therapy with basiliximab or rabbit anti-thymocyte globulin, in the peritransplant period.” NCT01950819 ↗ “The patients also receive rabbit Antithymocyte Globulin (rATG), tacrolimus, and sirolimus.” NCT02166177 ↗ Show 40 more sources
Known as	anti-human T-lymphocyte immunoglobulin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03357159 ↗
Known as	Anti-Lymphocyte-Globulin	“ATG FRESENIUS (Anti-Lymphocyte-Globulin)” NCT00678275 ↗
Known as	Anti-T-Lymphocyte Globulin	“Anti-T-Lymphocyte Globulin (ATG)” NCT00733733 ↗
Known as	Anti-thymoglobulin, rabbit (ATG, rabbit ATG)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00186628 ↗
Known as	antithymocyte globulin	“reduced intensity preparative regimen that included fludarabine, cyclophosphamide and antithymocyte globulin, allowed engraftment of donor stem cells in subjects with SAA” NCT01129323 ↗ 2 “assessing the efficacy and safety of antithymocyte globulin (ATG-Fresenius) plus tacrolimus monotherapy at gradually decreasing doses.” PMID 20883560 ↗ Oct 2010 “anti-thymocyte globulin (ATG) will be used to condition the recipients for transplantation” NCT00325741 ↗
Known as	antithymocyte globulin (rabbit)	“Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)” NCT03615144 ↗ 19 NCT04066114 ↗ NCT00566696 ↗ NCT03531736 ↗ NCT01856257 ↗ NCT01621477 ↗ NCT02188719 ↗ NCT07257419 ↗ NCT03600909 ↗ NCT01050764 ↗ NCT00260689 ↗ Show 9 more sources
Known as	Antithymocyte Immunoglobulin (Rabbit)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04114188 ↗ 1 NCT03789006 ↗
Known as	ATG	“We initiated a prospective randomized controlled trial of polyclonal rabbit anti-T-cell globulin (ATG) in patients with type 1 diabetes within 4 weeks of diagnosis and with...” PMID 17491669 ↗ Aug 2004 10 “Determine the safety and tolerability, in terms of clinical and laboratory toxicity, of anti-thymocyte globulin (ATG) combined with sirolimus in patients with relapsed multiple myeloma.” NCT00317798 ↗ “Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3.” NCT00186823 ↗ “Single shot of a polyclonal antilymphocyte preparation (ATG-Fresenius - 8 mg/kg, or IMTIX-Sangstat ATG 4 mg/kg/day).” NCT00316810 ↗ “received rabbit anti-thymocyte globulin (ATG) 3 mg/kg on day 8 post-transplant.” PMID 34373186 ↗ Aug 2021 “Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV” NCT04202835 ↗ “ATG FRESENIUS (Anti-Lymphocyte-Globulin)” NCT00678275 ↗ “Anti-T-Lymphocyte Globulin (ATG)” NCT00733733 ↗ NCT02218437 ↗ NCT05482542 ↗ NCT05634915 ↗
Known as	ATG (Anti-Thymocyte Globulin)	“ATG (Anti-Thymocyte Globulin)” NCT02188719 ↗
Known as	ATG Fresenius S	“The purpose of this study is to assess the efficacy and safety of the study drug, known as "ATG Fresenius S," which is sometimes called "EZ-2053," to prevent a lung transplant...” NCT00105183 ↗ 1 “anti-human T-lymphocyte immunoglobulin (ATLG, Grafalon®, formerly ATG-Fresenius S, Neovii Pharmaceuticals)” NCT03357159 ↗
Known as	ATG-F	“The two commonly used ATGs, Thymoglobulin and ATG-F have slightly different antigen profile and antibody concentrations.” PMID 27855166 ↗ Nov 2016 1 NCT02523768 ↗
Known as	ATG-Fresenius	“The ATG-Fresenius® is administered by slow infusion over four hours after antihistamine (2 bulbs Polaramine® IV) and intravenous methylprednisolone (minimum 30mg); it is...” NCT02523768 ↗ 13 “Patients who fulfill the inclusion criteria and give their informed consent to participate in the study will be randomized to be treated either with a course of ATG-Fresenius...” NCT00190502 ↗ “Patients enrolled in the study will be randomized to receive ATG (Fresenius) at a dosage of either 30 mg/Kg (10 mg/Kg on days -4, -3 and -2) or 15 mg/Kg (5 mg/Kg on days -4, -3 and -2).” NCT00934557 ↗ “All patients received rATG for 4 days [ATG-Fresenius (ATG-F) 4 mg/kg/day or Thymoglobulin (Thymo-S) 1.25 mg/kg/day] plus MMF and short-term corticosteroids.” PMID 15814548 ↗ May 2005 “assessing the efficacy and safety of antithymocyte globulin (ATG-Fresenius) plus tacrolimus monotherapy at gradually decreasing doses.” PMID 20883560 ↗ Oct 2010 “Single shot of a polyclonal antilymphocyte preparation (ATG-Fresenius - 8 mg/kg, or IMTIX-Sangstat ATG 4 mg/kg/day).” NCT00316810 ↗ “ATG-Fresenius 20 mg/kg day -4 to -2” NCT01582048 ↗ “ATG-Fresenius versus ATG” NCT03631563 ↗ NCT00733733 ↗ NCT00678275 ↗ NCT00934557 ↗ Show 3 more sources
Known as	ATLG	“Although rabbit anti-T-lymphocyte globulin (ATLG) is largely used for the prevention of immune-mediated complications” PMID 28705454 ↗ Jul 2017 1 “anti-human T-lymphocyte immunoglobulin (ATLG, Grafalon®, formerly ATG-Fresenius S, Neovii Pharmaceuticals)” NCT03357159 ↗
Known as	EZ-2053	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00105183 ↗
Known as	Grafalon	“anti-human T-lymphocyte immunoglobulin (ATLG, Grafalon®, formerly ATG-Fresenius S, Neovii Pharmaceuticals)” NCT03357159 ↗
Known as	IMTIX-Sangstat ATG	“Single shot of a polyclonal antilymphocyte preparation (ATG-Fresenius - 8 mg/kg, or IMTIX-Sangstat ATG 4 mg/kg/day).” NCT00316810 ↗
Known as	Lapine T-Lymphocyte Immune Globulin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05457556 ↗ 4 NCT04776850 ↗ NCT04521946 ↗ NCT04083183 ↗ NCT04530487 ↗
Known as	r-ATG	“Within 3 weeks of the apheresis stem cell collection, the first group's participants will be admitted to the hospital and will undergo a five-day conditioning regimen...” NCT00230035 ↗ 16 “All patients received either rabbit antithymocyte globulin (rATG) or interleukin 2 receptor antagonists (IL-2RA) in addition to tacrolimus (FK), mycophenolate mofetil (MMF),...” PMID 25557762 ↗ Jan 2015 “Rabbit anti-thymocyte globulin (rATG), a polyclonal rabbit-derived antibody that depletes lymphocytes, including T cells, was introduced to prevent GVHD and transplant rejection.” NCT05634915 ↗ “Describe the pharmacokinetics of rabbit anti-thymocyte globulin (rATG) in patients receiving allogeneic transplantation and determine the frequency of rATG antibody development” NCT00186823 ↗ “The first investigational conditioning regimen is cyclophosphamide (chemotherapy) and rATG (rabbit anti-thymocyte globulin, a protein against immune cells).” NCT05482542 ↗ “A Pilot, Phase-I Trial of Rabbit Anti-Thymocyte Globulin (rATG, Thymoglobulin™) in Combination With Rapamycin in Relapsed Multiple Myeloma (MM)” NCT00317798 ↗ “HPSC infusion will be preceded by a conditioning regimen of total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (rATG).” NCT05525507 ↗ “Our previous case report has shown promising results for rabbit antithymocyte globulin (rATG) in the treatment of Graves' orbitopathy.” PMID 35615718 ↗ May 2022 “The patients also receive rabbit Antithymocyte Globulin (rATG), tacrolimus, and sirolimus.” NCT02166177 ↗ “rabbit anti-thymocyte immunoglobulin (r-ATG) 3 mg/kg/d x 5 days” NCT06009965 ↗ “Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)” NCT00943800 ↗ Show 6 more sources
Known as	Rabbit Anti-Human Thymocyte Globulin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00316810 ↗
Known as	rabbit anti-T-lymphocyte globulin	“Although rabbit anti-T-lymphocyte globulin (ATLG) is largely used for the prevention of immune-mediated complications” PMID 28705454 ↗ Jul 2017
Known as	Rabbit Anti-thymocyte globulin (ATG)	“Rabbit Anti-thymocyte globulin (ATG)” NCT01565616 ↗
Known as	rabbit anti-thymocyte immunoglobulin	“rabbit anti-thymocyte immunoglobulin (r-ATG) 3 mg/kg/d x 5 days” NCT06009965 ↗ 1 NCT03099122 ↗
Known as	rabbit antithymocyte globulin (RATG)	“rabbit antithymocyte globulin (RATG)” NCT01517984 ↗
Known as	Rabbit ATG	“Patients will receive rabbit ATG 2.5 mg/kg on Day -2 and -1 (total 5 mg/kg)” NCT07570745 ↗ 20 “rabbit ATG at 1.5 mg/kg i.v. on days -11 through -7 pretransplantation” NCT00325741 ↗ “alemtuzumab will be replaced with rabbit ATG on days -10 through -7” NCT02165007 ↗ “rabbit ATG (2.0 mg/kg/day) day -5,-4,-3, and -2” NCT01461837 ↗ NCT05736419 ↗ NCT02143830 ↗ NCT00038857 ↗ NCT02828592 ↗ NCT01129323 ↗ NCT06412497 ↗ NCT01745913 ↗ Show 10 more sources
Known as	Thymoglobulin	“Patients will also receive rabbit antithymocyte globulin (Thymoglobulin) at a dose of 2 mg/kg IV daily for 3 days on transplant days -4, -3, and -2.” NCT01455506 ↗ 5 “A Pilot, Phase-I Trial of Rabbit Anti-Thymocyte Globulin (rATG, Thymoglobulin™) in Combination With Rapamycin in Relapsed Multiple Myeloma (MM)” NCT00317798 ↗ “rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France)” NCT07677306 ↗ “Rabbit antithymocyte globulin (rATG; thymoglobulin, Genzyme)” PMID 22544699 ↗ Apr 2012 “rabbit anti-thymocyte globulin (rATG, Thymoglobulin®)” NCT05385432 ↗ “Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)” NCT03615144 ↗
Known as	Thymoglobuline	“ATG (Thymoglobuline, rabbit) was used as 1 mg/kg/d from day -5 to day -3 and 2 mg/kg/d on day -2.” NCT05214066 ↗ 1 “rabbit antithymocyte globulin (ATG, Thymoglobuline®)” NCT01530555 ↗
Action	Deplete	“pre-transplant antibody-mediated T cell depletion” NCT00436722 ↗
Modality	Protein / enzyme biologic	“Anti-human-T-lymphocyte Immune Globulin, Rabbit (EZ-2053)” NCT00105183 ↗
Route	Intravenous	“single IV infusion” NCT00105183 ↗